CAS No. |
256925-92-5 |
中文名称 |
(2S,3R,4S,5S)-2-[[(2aR,4S,6aR,7aS,9aR,9bR,10R,12R,13S,14aS,15R,15aS,15bR)-15-羟基-13-(2-羟基丙-2-基)-3,3,9a,10,15a-五甲基十八氢-7H-12,14a-环氧环丙并[1',8a']萘并[2',1':4,5]茚并[2,1-b]氧杂䓬-4-基]氧基]四氢-2H-吡喃-3,4,5-三醇 |
英文名称 |
(2S,3R,4S,5S)-2-(((2aR,4S,6aR,7aS,9aR,9bR,10R,12R,13S,14aS,15R,15aS,15bR)-15-hydroxy-13-(2-hydroxypropan-2-yl)-3,3,9a,10,15a-pentamethyloctadecahydro-7H-12,14a-epoxycyclopropa[1',8a']naphtho[2',1':4,5]indeno[2,1-b]oxepin-4-yl)oxy)tetrahydro-2H-pyran-3,4,5-triol |
别名 |
AKOS032948479 | alpha-L-Arabinopyranoside, (3beta,15alpha,16alpha,23R,24S)-16,23:16,24-diepoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl | UNII-4DC28J6R1K | SCHEMBL4921749 | Q27259441 | (2S,3R,4S,5S)-2-[[(1S,2R,3S,4R,7R,9S,12R,14S,17R,18R,19R,21R,22S)-2-hyd |
标准英文名 |
(2S,3R,4S,5S)-2-(((2aR,4S,6aR,7aS,9aR,9bR,10R,12R,13S,14aS,15R,15aS,15bR)-15-hydroxy-13-(2-hydroxypropan-2-yl)-3,3,9a,10,15a-pentamethyloctadecahydro-7H-12,14a-epoxycyclopropa[1',8a']naphtho[2',1':4,5]indeno[2,1-b]oxepin-4-yl)oxy)tetrahydro-2H-pyran-3,4,5-triol |
MDL No. |
MFCD04040755 |
分子式 |
C35H56O9 |
分子量 |
620.82
|
精确分子量 |
620.39
|
SMILES |
C[C@@H]1C[C@H]2O[C@@]3(O[C@@H]2C(C)(C)O)[C@H](O)[C@@]2(C)[C@@H]4CC[C@H]5C(C)(C)[C@@H](O[C@@H]6OC[C@H](O)[C@H](O)[C@H]6O)CC[C@@]56C[C@@]46CC[C@]2(C)[C@@H]13 |
标准SMILES |
C[C@@H]1C[C@H]2O[C@]3(O[C@@H]2C(C)(C)O)[C@H]1[C@@]1(C)CC[C@@]24C[C@]52CC[C@H](O[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O)C(C)(C)[C@@H]5CC[C@H]4[C@]1(C)[C@H]3O |
用途 |
Cimiracemoside C is an active constituent of Cimicifuga with potential anti-diabetic effects through activation of AMPK. |
InChIKey |
BTPYUWOBZFGKAI-BKJHYQRZSA-N |